A Preview Of Medicenna Therapeutics Earnings
Medicenna Therapeutics (NASDAQ:MDNA) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.
Medicenna Prices 3,333,334 Unit Offering At $1.50/Unit
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketedMedicenna Therapeutics Corp.
Medicenna’s Lead Cancer Program Shows Preliminary Anti-Cancer Activity In Solid Tumor Study
Medicenna Therapeutics Corp (NASDAQ:MDNA) announced new clinical data from the Phase 1/2 ABILITY study of MDNA11. The data provide preliminary evidence…
Medicenna Announces New Clinical Data Providing Preliminary Evidence Of MDNA11’s Single Agent Anti-Cancer Activity In The Phase 1/2 ABILITY Study
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts
--
Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday’s Pre-Market Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 22.1% to $0.2050 in pre-market trading. Allena Pharmaceuticals disclosed a new meeting date and new record date for special meeting to approve reverse stock split.
MDNA: Encouraging CD8+ T Cell and NK Cell Responses in ABILITY Trial…
By David Bautz, PhD
NASDAQ:MDNA
READ THE FULL MDNA RESEARCH REPORT
Oppenheimer Maintains Outperform on Medicenna Therapeutics, Lowers Price Target to $10
Oppenheimer analyst Matthew Biegler maintains Medicenna Therapeutics (NASDAQ:MDNA) with a Outperform and lowers the price target from $12 to $10.
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.